Lansoprazole + Tinidazole + Clarithromycin CombipackThird Party Manufacturing in India

This combipack combines three active pharmaceutical ingredients that work through complementary mechanisms to eradicate Helicobacter pylori infection. Lansoprazole, a substituted benzimidazole proton pump inhibitor, accumulates in the acidic environment of gastric parietal cell canaliculi where it is converted to active sulfenamide metabolites that form covalent disulfide bonds with cysteine residues of the H⁺/K⁺-ATPase enzyme. This irreversible inhibition shuts down the final step of gastric acid secretion, raising intragastric pH and creating an optimal environment for the antibiotics to work effectively against H. pylori. Tinidazole, a 5-nitroimidazole derivative, enters bacterial and protozoal cells where its nitro group is reduced by bacterial nitroreductases to generate toxic nitro radicals that cause extensive DNA strand breakage and inhibition of nucleic acid synthesis. This cytotoxic action targets both the spiral and coccoid forms of H. pylori. Clarithromycin, a semisynthetic macrolide antibiotic, binds reversibly to the 50S ribosomal subunit of susceptible bacteria, specifically to domain V of the 23S rRNA component, thereby inhibiting peptide translocation and blocking protein synthesis at the chain elongation step. The triple combination achieves synergistic eradication rates exceeding 85% in clinical settings, making it a cornerstone of first-line H. pylori eradication therapy worldwide.

Therapeutic Uses

Lansoprazole + Tinidazole + Clarithromycin Combipack is indicated for the eradication of Helicobacter pylori infection in patients with active chronic gastritis, duodenal ulcer, and gastric ulcer.

• H. pylori Eradication in Peptic Ulcer Disease: The primary indication is the eradication of H. pylori in patients with active or recurrent peptic ulcers. Triple therapy achieves significantly higher cure rates compared to dual therapy or monotherapy.
• Chronic Gastritis: H. pylori-associated chronic active gastritis is effectively treated with this regimen, reducing inflammation and the long-term risk of atrophic gastritis.
• MALT Lymphoma: Eradication therapy is the first-line treatment for H. pylori-positive low-grade gastric MALT lymphoma, with durable remission achievable in over 70% of cases.
• Prevention of Ulcer Recurrence: Successful H. pylori eradication reduces ulcer recurrence rates from approximately 60-80% per year to under 10%.

Why Manufacturers Choose This Combipack

Triple therapy combipacks for H. pylori eradication are among the highest-volume gastrointestinal products in the Indian pharmaceutical market. This combipack presents a significant opportunity for third-party manufacturers, as hospitals and clinics consistently prescribe this regimen for their ulcer patients. The combipack format simplifies dispensing and improves patient compliance compared to prescribing three separate medicines. Indian manufacturers benefit from the well-established supply chain for all three APIs, each of which has been manufactured in India for decades. The combination enjoys WHO-GMP certification across a wide network of Indian manufacturing facilities, and the product is exported to Africa, Southeast Asia, and the Middle East in large volumes. This makes the combipack one of the most sought-after products for PCD franchise operators and export-oriented pharmaceutical companies.